thalidomide has been researched along with Granulomatous Disease, Chronic in 6 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Granulomatous Disease, Chronic: A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide has a favorable safety profile compared with other alternatives and could be considered a feasible therapeutic option for this type of condition in selected patients." | 5.43 | Chronic Recurrent Multifocal Osteomyelitis and Thalidomide in Chronic Granulomatous Disease. ( Barber, I; Fernández-Polo, A; Fontecha, CG; Martín-Nalda, A; Martinez-Gallo, M; Roca, I; Soler-Palacin, P, 2016) |
| "Thalidomide has a favorable safety profile compared with other alternatives and could be considered a feasible therapeutic option for this type of condition in selected patients." | 1.43 | Chronic Recurrent Multifocal Osteomyelitis and Thalidomide in Chronic Granulomatous Disease. ( Barber, I; Fernández-Polo, A; Fontecha, CG; Martín-Nalda, A; Martinez-Gallo, M; Roca, I; Soler-Palacin, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawai, T | 2 |
| Watanabe, N | 1 |
| Yokoyama, M | 1 |
| Arai, K | 1 |
| Oana, S | 1 |
| Harayama, S | 1 |
| Yasui, K | 1 |
| Oh-Ishi, T | 1 |
| Onodera, M | 1 |
| Noel, N | 1 |
| Mahlaoui, N | 1 |
| Blanche, S | 2 |
| Suarez, F | 2 |
| Coignard-Biehler, H | 1 |
| Durieu, I | 1 |
| Godeberge, P | 1 |
| Sokol, H | 2 |
| Catherinot, E | 1 |
| Poiree, S | 1 |
| Chapdelaine, H | 1 |
| Dunogue, B | 1 |
| Bodemer, C | 1 |
| Lecuit, M | 1 |
| Fischer, A | 1 |
| Lortholary, O | 1 |
| Hermine, O | 2 |
| Martín-Nalda, A | 1 |
| Roca, I | 1 |
| Fontecha, CG | 1 |
| Fernández-Polo, A | 1 |
| Barber, I | 1 |
| Martinez-Gallo, M | 1 |
| Soler-Palacin, P | 1 |
| Meatchi, T | 1 |
| Malamut, G | 1 |
| Pocidalo, MA | 1 |
| Cellier, C | 1 |
| Aguilera, DG | 1 |
| Tomita, T | 1 |
| Rajaram, V | 1 |
| Fangusaro, J | 1 |
| Katz, BZ | 1 |
| Shulman, S | 1 |
| Goldman, S | 1 |
1 review available for thalidomide and Granulomatous Disease, Chronic
| Article | Year |
|---|---|
[A therapeutic approach towards chronic granulomatous disease].
Topics: Cytokines; Genetic Therapy; Genetic Vectors; Granulomatous Disease, Chronic; Hematopoietic Stem Cell | 2014 |
5 other studies available for thalidomide and Granulomatous Disease, Chronic
| Article | Year |
|---|---|
Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease.
Topics: Adenosine Triphosphate; Caspase 1; Cells, Cultured; Child, Preschool; Cytokines; Granulomatous Disea | 2013 |
Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series.
Topics: Adolescent; Child; Child, Preschool; Female; Granulomatous Disease, Chronic; Humans; Immunosuppressi | 2013 |
Chronic Recurrent Multifocal Osteomyelitis and Thalidomide in Chronic Granulomatous Disease.
Topics: Child; Granulomatous Disease, Chronic; Humans; Immunosuppressive Agents; Male; Osteomyelitis; Radion | 2016 |
Thalidomide as a treatment for refractory CGD colitis.
Topics: Biopsy; Colitis; Diagnosis, Differential; Follow-Up Studies; Granulomatous Disease, Chronic; Humans; | 2009 |
Glioblastoma multiforme in a patient with chronic granulomatous disease treated with subtotal resection, radiation, and thalidomide: case report of a long-term survivor.
Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Diagnosis, Differential; Female; | 2009 |